VIVO BIO TECH
YOUR TRUSTED PRECLINICAL PARTNER

November 11, 2026

To,
The Manager
Dept of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001

Dear Sir/Madam,

Subject : **Outcome of the Board Meeting - Submission of Unaudited Standalone & Consolidated Financial Results for the Second Quarter ended September 30, 2026.**
Reference : **Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**
Scrip : **511509**

With reference to the above cited subject, we bring to your kind notice that the Board of Directors of the Company at their meeting held today, i.e. Wednesday, November 11, 2026, *inter-alia*, transacted the following business:

1. Considered and approved the Unaudited Standalone & Consolidated Financial Results of the Company for the Second quarter ended September 30, 2026.

   A copy of the signed Results along with Limited Review Report issued by the Statutory Auditors M/s. P. Murali & Co., Chartered Accountants, are enclosed as **Annexure – A.**

The meeting commenced at 06:30 p.m. and concluded at 07:00 p.m.

This is for your information and records.

Thanking You,

Yours faithfully
For Vivo Bio Tech Limited
BHAVISH VIJAY VARGIYA
Digitally signed by BHAVISH VIJAY VARGIYA
Date: 2026.11.11 19:10:29 +05'30'

Bhavish Vijayvargiya
Company Secretary & Compliance Officer
M. No. A77631

Encl. as above

Vivo Bio Tech Limited
03rd Floor, Ilyas Mohammed Khan Estate, 8-2-672/5&6,
Road No.1, Banjara Hills, Hyderabad-500034
E-mail:investors@vivobio.com CIN: L65993TG1987PLC007163

VIVO BIO TECH
YOUR TRUSTED PRECLINICAL PARTNER

UN-AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER & HALF-YEAR ENDED SEPTEMBER 30, 2026

Rs. in Lacs

S.No.	Particulars	Quarter Ended			Half-Year Ended		Year Ended
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
I	Revenue from Operations	1,698.62	1,413.94	1,301.66	3,112.56	2,543.52	5,256.84
II	Other Income	104.50	5.54	13.39	110.04	27.17	44.08
III	**Total Income**	**1,803.13**	**1,419.48**	**1,315.05**	**3,222.60**	**2,570.69**	**5,300.93**
IV	**Expenses**						
	a) Increase/(decrease) in Stock in Trade and WIP	123.14	(100.50)	98.76	22.64	85.90	-36.19
	b) Consumption of Raw Materials	-	-	-	-	-	-
	c) Purchase of Traded Goods	248.52	286.13	110.72	534.65	274.19	848.90
	d) Employees Cost	467.05	459.29	398.62	926.33	705.97	1,595.17
	e) Depreciation and Amortisation	375.04	353.17	256.83	728.20	521.24	1,062.67
	f) Finance Cost	201.68	123.76	146.80	325.44	297.12	584.88
	g) Administrative Expenditure	251.03	264.10	152.35	515.13	383.70	726.79
	Total	**1,666.45**	**1,385.95**	**1,164.08**	**3,052.40**	**2,268.12**	**4,782.22**
V	**Profit Before Tax & Exceptional Items (III-IV)**	**136.67**	**33.53**	**150.98**	**170.20**	**302.58**	**518.71**
	Exceptional Item	-	-	-	-	-	-
	Prior Period Items	-	-	-	-	-	(60.45)
VI	**Profit Before Tax**	**136.67**	**33.53**	**150.98**	**170.20**	**302.58**	**458.26**
VII	Tax Expense						
	a. Current Tax	37.16	24.83	77.95	61.99	156.92	81.02
	b. Deffered tax	33.24	(9.74)	(13.90)	23.50	(78.59)	570.86
	Total Tax Expense	**70.40**	**15.10**	**64.05**	**85.49**	**78.33**	**651.88**
	VIII Net Profit After Tax (V-VI)	**66.28**	**18.43**	**86.92**	**84.71**	**224.24**	**-193.61**
IX	Other Comprehensive Income						
	a.Items that will be Reclassified to Profit or Loss (Net of Tax)	-	-	-	-	-	-
X	**Total Other Comprehensive Income (VII+VIII+IX)**	**66.28**	**18.43**	**86.92**	**84.71**	**224.24**	**-193.61**
XI	Paid Up Share Capital (Face value of Rs.10/-) (In lakh Units)	2,219.06	2,219.06	2,210.06	2,219.06	2,210.06	2,219.06
XII	**Earnings per Equity Share:**						
	1) Basic	0.30	0.08	0.45	0.38	1.15	-0.93
	2) Diluted	0.30	0.08	0.45	0.38	1.15	-0.93

Place: Hyderabad
Date: 11/11/2026

VIVO BIO TECH LIMITED

For Vivo Bio Tech Limited

Kalyan Ram Mangipudi
Whole Time Director
DIN: 02012580

Vivo Bio Tech Limited
03rd Floor, Ilyas Mohammed Khan Estate, 8-2-672/5&6,
Road No.1, Banjara Hills, Hyderabad-500034
E-mail:investors@vivobio.com CIN: L65993TG1987PLC007163

VIVO BIO TECH
YOUR TRUSTED PRECLINICAL PARTNER

UN-AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & HALF-YEAR ENDED SEPTEMBER 30, 2026

Rs. in Lacs

S.No.	Particulars	Quarter Ended			Half-Year Ended		Year Ended
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
I	Revenue from Operations	1,719.15	1,427.97	1,310.90	3,147.12	2,562.06	5,333.47
II	Other Income	155.34	5.54	13.39	160.88	27.17	44.08
III	**Total Income**	**1,874.49**	**1,433.51**	**1,324.29**	**3,308.00**	**2,589.23**	**5,377.55**
IV	Expenses						
	a) Increase/(decrease) in Stock in Trade and WIP	123.14	(100.50)	98.76	22.64	85.90	-36.19
	b) Consumption of Raw Materials	-	-	-	-	-	-
	c) Purchase of Traded Goods	248.52	286.13	110.72	534.65	274.19	848.90
	d) Employees Cost	487.11	472.98	407.89	960.09	728.13	1,648.74
	e) Depreciation and Amortisation	375.04	353.17	256.83	728.20	521.24	1,062.67
	f) Finance Cost	201.68	123.76	146.80	325.44	297.12	584.88
	g) Administrative Expenditure	252.04	264.11	152.38	516.15	383.75	727.12
	Total	**1,687.53**	**1,399.65**	**1,173.38**	**3,087.18**	**2,290.33**	**4,836.12**
V	Profit Before Tax & Exceptional Item (III-IV)	**186.96**	**33.86**	**150.92**	**220.82**	**298.91**	**541.44**
	Expceptional Item	-	-	-	-	-	-
	Prior Period Items	-	-	-	-	-	(60.45)
VI	**Profit Before Tax**	**186.96**	**33.86**	**150.92**	**220.82**	**298.91**	**480.99**
VII	Tax Expense						
	a. Current Tax	43.51	24.83	77.95	68.35	156.92	81.02
	b. Deffered tax	33.24	(9.74)	(13.90)	23.50	(78.59)	570.86
	Total Tax Expense	**76.75**	**15.10**	**64.05**	**91.85**	**78.33**	**651.88**
	VIII Net Profit After Tax (V-VI)	**110.21**	**18.76**	**86.86**	**128.97**	**220.57**	**-170.88**
IX	Minority Interest	-	-	-	-	-	-
X	Other Comprehensive Income						
	a.Items that will be Reclassified to Profit or Loss (Net of Tax)	-	-	-	-	-	-
XI	**Total Other Comprehensive Income (VII+VIII+IX)**	**110.21**	**18.76**	**86.86**	**128.97**	**220.57**	**-170.88**
XII	Paid Up Share Capital (Face value of Rs.10/-) (In lakh Units)	2,219.06	2,219.06	2,210.06	2,219.06	2,210.06	2,219.06
XIII	**Earnings per Equity Share:**						
	1) Basic	0.50	0.08	0.45	0.58	1.14	-0.82
	2) Diluted	0.50	0.08	0.45	0.58	1.14	-0.82

Place: Hyderabad
Date: 11/11/2026

VIVO BIO TECH LIMITED

For Vivo Bio Tech Limited

Kalyan Ram Mangipudi
Whole Time Director
DIN: 02012580

Vivo Bio Tech Limited
03rd Floor, Ilyas Mohammed Khan Estate, 8-2-672/5&6,
Road No.1, Banjara Hills, Hyderabad-500034
E-mail:investors@vivobio.com CIN: L65993TG1987PLC007163

VIVO BIO TECH
YOUR TRUSTED PRECLINICAL PARTNER

STATEMENT OF ASSETS AND LIABILITIES AS AT SEPTEMBER 30, 2026

Rs. in Lacs

Particulars	Standalone			Consolidated		
	30.09.2026	30.09.2025	31.03.2026	30.09.2026	30.09.2025	31.03.2026
	Un-Audited	Un-Audited	Audited	Un-Audited	Un-Audited	Audited
I. ASSETS						
Non-Current Assets						
Fixed Assets						
Property, Plant and Equipment	7,131.34	5,809.07	6,843.91	7,447.96	6,145.09	7,179.93
Capital Work-In-Progress	1,616.23	1,285.91	480.74	1,616.23	1,285.91	480.74
Intangible Assets	4,772.15	2,170.80	5,122.68	4,772.15	2,170.80	5,122.68
Financial Assets						
Non-Current Investments	2,373.50	4.00	2,195.00	2,369.50	-	2,191.00
Long Term Loans and Advances	-	-	-		-	-
Other Non Current Assets	30.66	18.61	27.19	30.66	18.61	27.19
Deferred Tax Asset		-	-		-	-
Total Non-Current Assets	**15,923.87**	**9,288.38**	**14,669.51**	**16,236.50**	**9,620.41**	**15,001.53**
Current Assets						
Inventories	792.60	693.15	815.24	792.60	693.15	815.24
Financial Assets						
Trade Receivables	1,809.08	1,417.02	1,174.71	1,809.08	1,417.02	1,174.71
Cash and Cash Equivalents	277.95	126.18	130.30	291.16	133.23	143.55
Short Term Loans and Advances	424.64	3,925.66	596.46	435.32	4,531.96	607.14
Other Current Assets	151.87	121.45	100.02	153.55	121.82	101.00
Total Current Assets	**3,456.13**	**6,283.47**	**2,816.72**	**3,481.70**	**6,897.19**	**2,841.64**
TOTAL ASSETS = I	**19,380.01**	**15,571.85**	**17,486.23**	**19,718.20**	**16,517.59**	**17,843.17**
II. EQUITY AND LIABILITIES						
Equity						
Equity Share Capital	2,219.06	2,210.06	2,219.06	2,219.06	2,210.06	2,219.06
Other Equity	7,025.50	7,327.14	6,940.79	7,063.92	7,294.91	6,934.95
Money Received Against Share Warrants	161.76	171.89	161.76	161.76	171.89	161.76
Total Equity	**9,406.33**	**9,709.10**	**9,321.62**	**9,444.75**	**9,676.86**	**9,315.78**
Liabilities						
Non Current liabilities						
Financial Liabilities						
Borrowings	5,687.19	2,805.68	4,314.65	5,980.49	3,783.32	4,660.94
Long Term Provisions	112.52	84.38	95.41	112.52	84.38	95.41
Defferred Tax Liabilities	771.32	98.37	747.82	771.32	98.37	747.82
Total Non Current Liabilities	**6,571.03**	**2,988.43**	**5,157.87**	**6,864.33**	**3,966.07**	**5,504.16**
Current Liabilities						
Financial Liabilities						
Borrowings	2,282.62	1,869.83	2,077.11	2,282.62	1,869.83	2,077.11
Trade Payables & Other Current Liabilities	265.00	164.77	179.92	265.00	164.77	196.17
Provisions	855.03	839.72	749.71	861.50	840.06	749.95
Total Current Liabilities	**3,402.65**	**2,874.33**	**3,006.74**	**3,409.12**	**2,874.67**	**3,023.23**
TOTAL EQUITY & LIABILITIES = II	**19,380.01**	**15,571.85**	**17,486.23**	**19,718.20**	**16,517.59**	**17,843.17**

Place: Hyderabad
Date: 11/11/2026

VIVO BIO TECH LIMITED

For Vivo Bio Tech Limited

Kalyan Ram Mangipudi
Whole Time Director
DIN: 02012580

Vivo Bio Tech Limited
03rd Floor, Ilyas Mohammed Khan Estate, 8-2-672/5&6,
Road No.1, Banjara Hills, Hyderabad-500034
E-mail:investors@vivobio.com CIN: L65993TG1987PLC007163

VIVO BIO TECH
YOUR TRUSTED PRECLINICAL PARTNER

STANDALONE CASH FLOW STATEMENT FOR THE HALF-YEAR ENDED SEPTEMBER 30, 2026

Rs. in Lacs

S.No.	PARTICULARS	As at 30.09.2026 Un-Audited	As at 30.09.2025 Un-Audited	As at 31.03.2026 Audited
A	**Cash Flow from Operating Activities:**			
	Net Profit/ (Loss) before Taxation and Extraordinary Items	170.20	302.58	458.26
	Adjustments for:			
	Depreciation	728.20	518.48	1,068.49
	Amortised Expenses		2.76	(5.82)
	Profit on sale of Property, Plant and Equipment	105.63	-	-
	Interest Expenses	325.44	297.12	584.88
	Operating Profit before Working Capital Changes	**1,118.23**	**1,120.94**	**2,105.81**
	Changes in Assets & Liabilities:			
	Trade and Other Receivables including Inventory	(495.24)	(1,947.03)	1,523.83
	Trade and Other Payables	413.03	97.17	240.62
	Cash Generated from Operations	**1,036.01**	**(728.92)**	**3,870.26**
	Interest Paid	115.58	79.84	178.59
	Taxation for the year	61.99	156.92	81.02
	Net Cash Generated from / (Used in) Operating Activities	**858.44**	**(965.68)**	**3,610.65**
B	**Cash Flow from Investing Activities:**			
	Purchase of Fixed Assets	(1,800.60)	(12.19)	(3,743.75)
	Profit on sale of Property, Plant and Equipment	105.63	-	-
	Investment	(178.50)	-	(2,191.00)
	Net Cash Used in Investing Activities	**(1,873.47)**	**(12.19)**	**(5,934.75)**
	Cash Flow from Financial Activities:			
	Proceeds from Equity Shares	0.00	1,665.83	1,696.21
	Interest & Finance Cost	(209.86)	(217.28)	(406.29)
	Net Proceeds from Long Term Borrowings	1,372.54	(465.38)	1,043.59
	Net Cash Generated from Financing Activities	**1,162.68**	**983.16**	**2,333.52**
	Net Increase in Cash and Cash Equivalents	**147.64**	**5.29**	**9.42**
	Cash and Cash Equivalents as at Beginning of the Period	130.31	120.89	120.89
	Cash and Cash Equivalents as at end of the Period	**277.95**	**126.18**	**130.31**

Place: Hyderabad
Date: 11/11/2026

VIVO BIO TECH LIMITED

For Vivo Bio Tech Limited

Kalyan Ram Mangipudi
Whole Time Director
DIN: 02012580

Vivo Bio Tech Limited
03rd Floor, Ilyas Mohammed Khan Estate, 8-2-672/5&6,
Road No.1, Banjara Hills, Hyderabad-500034
E-mail:investors@vivobio.com CIN: L65993TG1987PLC007163

VIVO BIO TECH
YOUR TRUSTED PRECLINICAL PARTNER

CONSOLIDATED CASH FLOW STATEMENT FOR THE HALF-YEAR ENDED SEPTEMBER 30, 2026

Rs. in Lacs

S.No.	PARTICULARS	As at 30.09.2026 Un-Audited	As at 30.09.2025 Un-Audited	As at 31.03.2026 Audited
A	**Cash Flow from Operating Activities:**			
	Net Profit/ (Loss) before Taxation and Extraordinary Items	220.82	298.91	480.99
	Adjustments for:			
	Depreciation	728.20	518.48	1,068.49
	Amortised Expenses	-	2.76	(5.82)
	Profit on sale of Property, Plant and Equipment	156.47	-	-
	Interest Expenses	325.44	297.12	584.88
	Operating Profit before Working Capital Changes	**1,118.00**	**1,117.26**	**2,128.54**
	Changes in Assets & Liabilities:			
	Trade and Other Receivables including Inventory	(495.93)	(2,698.35)	1,367.51
	Trade and Other Payables	403.01	97.04	256.64
	Cash Generated from Operations	**1,025.09**	**(1,484.04)**	**3,752.69**
	Interest Paid	115.58	79.84	178.59
	Taxation for the year	68.35	156.92	81.02
	Net Cash Generated from / (Used in) Operating Activities	**841.16**	**(1720.80)**	**3493.08**
B	**Cash Flow from Investing Activities:**			
	Purchase of Fixed Assets	(1,781.19)	(12.20)	(3,743.75)
	Profit on sale of Property, Plant and Equipment	156.47	-	-
	Investment	(178.50)	-	(2,191.00)
	Net Cash Used in Investing Activities	**(1803.23)**	**(12.20)**	**(5934.75)**
	Cash Flow from Financial Activities:			
	Proceeds from Equity Shares	0.00	1,665.84	1,696.21
	Interest & Finance Cost	(209.86)	(217.28)	(406.29)
	Net Proceeds from Long Term Borrowings	1,319.55	289.62	1,167.24
	Net Cash Generated from Financing Activities	**1109.68**	**1738.17**	**2457.16**
	Net Increase in Cash and Cash Equivalents	**147.61**	**5.17**	**15.49**
	Cash and Cash Equivalents as at Beginning of the Year	143.55	128.06	128.06
	Cash and Cash Equivalents as at end of the Period	**291.16**	**133.23**	**143.55**

Place: Hyderabad
Date: 11/11/2026

For Vivo Bio Tech Limited

VIVO BIO TECH LIMITED

Kalyan Ram Mangipudi
Whole Time Director
DIN: 02012580

Notes:

1. The above Un-Audited Financial Results for the Quarter and Half Year ended September 30, 2026, were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on November 11, 2026.

2. The figures for the quarter ended March 31, 2026 are the balancing figure between the audited figures of the full financial year and the published year-to-date figures upto the 3rd quarter of respective financial years which were subject to Limited Review by the Statutory Auditor of the Company.

3. The Un-Audited Financial Results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of Companies Act, 2013 ('The Act') read with relevant rules issued thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

4. The Consolidated Results include results of all subsidiaries, viz., Vivobio Labs Private Limited, Vivobio Discovery Services Private Limited, Surlogic Life Consultancy Private Limited and Vivobio Consulting Services Private Limited (Formerly Donakanti Consulting Services Private Limited).

5. The Company operates in single Segments Viz., Bio Technology. Hence segmental reporting is not required.

6. The above financial results are available on the stock exchange website www.bseindia.com and company's website www.vivobio.com.

7. Previous year's/period's figures are rearranged/ regrouped wherever necessary.

Date: November 11, 2026
Place: Hyderabad

For Vivo Bio Tech Limited

VIVO BIO TECH LIMITED

M. Kalyan Ram
Whole Time Director
DIN: 02012580

P. MURALI & CO.,
CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. T.G, INDIA

Tel. : (91-40) 2332 6666, 2331 2554
(91-40) 2339 3967,
(91-40) 2332 2119, 2331 7032

Email : pmurali.co@gmail.com
pmurali.tax@gmail.com
info@pmurali.com

Website : www.pmurali.com

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors
VIVO BIO TECH LIMITED

1. We have reviewed the accompanying statement of unaudited standalone financial results of **M/s. VIVO BIO TECH LIMITED** (the "Company") for the quarter ended 30th September, 2026 and for the period from 01st April, 2026 to 30th September, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting, ('Ind AS 34,') prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

P. MURALI & CO., Hyderabad Chartered Accountants

P. MURALI & CO.,
CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. T.G, INDIA

Tel. : (91-40) 2332 6666, 2331 2554
(91-40) 2339 3967,
(91-40) 2332 2119, 2331 7032

Email : pmurali.co@gmail.com
pmurali.tax@gmail.com
info@pmurali.com

Website : www.pmurali.com

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS 34 prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali& Co.
Chartered Accountants
FRN: 007257S

P. MURALI & CO. Hyderabad Chartered Accountants

Mukund Vijayrao Joshi
Partner
M. No. 024784
UDIN: 26024784MLFXMF8689

Place: Hyderabad
Date: 11-11-2026.

P. MURALI & CO.,
CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. T.G, INDIA

Tel. : (91-40) 2332 6666, 2331 2554
(91-40) 2339 3967,
(91-40) 2332 2119, 2331 7032

Email : pmurali.co@gmail.com
pmurali.tax@gmail.com
info@pmurali.com

Website : www.pmurali.com

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, as amended

TO
THE BOARD OF DIRECTORS OF
M/s. VIVO BIO TECH LIMITED

1. We have reviewed the accompanying statement of unaudited consolidated financial results of **VIVO BIO TECH LIMITED** (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), for the quarter ended 30th September, 2026 and for the period from 01st April, 2026 to 30th September, 2026 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting, ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

P. MURALI & CO. Hyderabad Chartered Accountants

P. MURALI & CO.,
CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. T.G, INDIA

Tel. : (91-40) 2332 6666, 2331 2554
(91-40) 2339 3967,
(91-40) 2332 2119, 2331 7032

Email : pmurali.co@gmail.com
pmurali.tax@gmail.com
info@pmurali.com

Website : www.pmurali.com

4. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the results of the following entities which are audited by us:

1. Vivo Bio Labs Private Limited
2. Vivo Bio Discovery Services Private Limited
3. Surlogic Life Consultancy Private Limited
4. Vivo Bio Consulting Services Private Limited (Formerly known as Donakanti Consultancy Services Private Limited)

5. Based on our review conducted and procedures performed as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali& Co.
Chartered Accountants
FRN: 007257S

P. MURALI & CO., Hyderabad, Chartered Accountants

Mukund Vijayrao Joshi
Partner
M.No. 024784
UDIN: 26024784LCBQUD9647

Place: Hyderabad
Date: 11-11-2026.